Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
What are hemodynamic indices that would sway you between MCS or foregoing it?
Related Questions
What are standard selection criteria for patients who are eligible for heart transplantation?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?
Do you recommend initiating treatment with an SGLT2 inhibitor or semaglutide first for a patient with obesity and heart failure with preserved ejection fraction?
What are reasonable alternatives to invasive angiography for CAV surveillance in patients who are a few years out from cardiac transplant with impaired renal function?
How do you weigh the benefit of urinary catheter placement for strict I/O measurement with the risk of avoidable CAUTI?
With the FDA recently approving acoramidis for ATTR cardiac amyloidosis, how should we decide on optimal drug therapy and options for our patients?
What is your approach when a patient has concomitant acute decompensated heart failure and rapid atrial fibrillation?
Does the presence of diastolic dysfunction guide subsequent pharmacological, pacing and ablative therapies for atrial fibrillation?